1. Development and characterization of a plant-derived rotavirus-like particle vaccine
- Author
-
Shigeki Hoshino, Natsuki Kurokawa, Manon Couture, Michèle Dargis, Naohisa Tsutsui, Sonia Trépanier, Tomohiro Koike, Marc-André D'Aoust, Masaaki Arai, and Pierre-Olivier Lavoie
- Subjects
Rotavirus ,Viral protein ,viruses ,medicine.medical_treatment ,Nicotiana benthamiana ,medicine.disease_cause ,Antibodies, Viral ,Vaccines, Attenuated ,complex mixtures ,Rotavirus Infections ,law.invention ,Virus-like particle ,law ,medicine ,Animals ,Vaccines, Virus-Like Particle ,Neutralizing antibody ,General Veterinary ,General Immunology and Microbiology ,biology ,Chemistry ,Immunogenicity ,Public Health, Environmental and Occupational Health ,Rotavirus Vaccines ,virus diseases ,biology.organism_classification ,Virology ,Rats ,Infectious Diseases ,Recombinant DNA ,biology.protein ,Molecular Medicine ,Rabbits ,Adjuvant - Abstract
Background Virus-like particles (VLPs) are unable to replicate in the recipient but stimulate the immune system through recognition of repetitive subunits. Parenterally delivered rotavirus-VLP (Ro-VLP) vaccine could have the potential to overcome the weaknesses of licensed oral live-attenuated rotavirus vaccines, namely, low efficacy in low-income and high mortality settings and a potential risk of intussusception. Methods A monovalent Ro-VLP composed of viral protein (VP) 7, VP6 and VP2 of G1 genotype specificity was produced in Nicotiana benthamiana using Agrobacterium tumefaciens infiltration-based transient recombinant expression system. Plants expressing recombinant G1 Ro-VLP were harvested, then the resultant biomass was processed through a series of clarification and purification steps including standard extraction, filtration, ultrafiltration and chromatography. The purified G1 Ro-VLP was subsequently examined for its immunogenicity and toxicological profile using animal models. Results G1 Ro-VLP had a purity of ≥90% and was structurally similar to triple-layered rotavirus particles as determined by cryogenic transmission electron microscopy. Two doses of aluminum hydroxide-adjuvanted G1 Ro-VLP (1 μg, 5 μg or 30 μg), administered intramuscularly, elicited a robust homotypic neutralizing antibody response in rats. Also, rabbits administered G1 Ro-VLP (10 μg or 30 μg) four times intramuscularly with aluminum hydroxide adjuvant did not show any significant toxicity. Conclusions Plant-derived Ro-VLP composed of VP7, VP6 and VP2 structural proteins would be a plausible alternative to live-attenuated oral rotavirus vaccines currently distributed worldwide.
- Published
- 2021